Comparing Anti-reflux Mucosal Valvuloplasty to Proton Pump Inhibitors for Treating Gastroesophageal Reflux Disease in Adults Aged 18 to 60
Led by Qilu Hospital of Shandong University · Updated on 2024-11-18
74
Participants Needed
1
Research Sites
160 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the relative benefits, safety, and effectiveness of Anti-reflux mucosal valvuloplasty ARMV compared to daily Proton Pump Inhibitors PPIs in patients with Gastroesophageal Reflux Disease GERD. This trial aims to better understand how ARMV, a minimally invasive procedure, compares to standard PPI treatment in managing GERD symptoms and improving patients quality of life.
The ARMV procedure is performed under general anesthesia, using an endoscope to release and reconstruct a segment of mucosa at the esophagogastric junction to form a mucosal flap. This flap is secured with metal clips to prevent flattening and promote reflux prevention. Patients continue PPI therapy for one month after ARMV to aid healing before stopping the medication. The comparison group continues PPI treatment with dosage adjustments based on symptom control. PPI use is carefully recorded in medication diaries.
Participants will undergo endoscopic examination and various follow-up assessments including symptom questionnaires, esophageal pH monitoring, and endoscopic evaluations over up to three years. Key outcomes include GERD-related quality of life, reflux scores, esophagitis presence, mucosal flap appearance, PPI usage, and adverse events. Researchers will closely monitor participants symptoms, medication use, and safety throughout the study period, which lasts until December 2028.
CONDITIONS
Brief Title
Anti-reflux Mucosal Valvuloplasty Versus PPIs for GERD Treatment
Research Team
J
jiaoyang j lu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Daily PPI use for at least 1 year or twice daily use for at least 8 weeks
Esophagitis Grade B, C, or D (Los Angeles Classification)
Hill's flap valve grade 3 or less
Distal esophageal pH less than 4 on 1-2 days in a 7-day period exceeding 5.3%
Normal or near-normal esophageal motility
Lower esophageal sphincter pressure between 5 and 15 mmHg
DeMeester score 14.7 or higher or total reflux episodes more than 73
Signed informed consent form
You will not qualify if you...
Body Mass Index over 35 kg/m2
ASA physical status greater than II
Barrett's esophagus
Hiatal hernia larger than 2 cm
Esophagitis Grade A or no esophagitis
Hill's flap valve grade greater than 3
Peptic ulcer disease
Primary esophageal motility disorders such as achalasia
Severe gastroparesis
History of previous esophageal or gastric surgery including ARMS or ARMA
Uncontrolled systemic diseases
Gastric outlet obstruction
Pregnancy or planning to become pregnant
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 1 month or more depending on treatment group and symptom control
Participants undergo either the anti-reflux mucosal valvuloplasty (ARMV) procedure under general anesthesia or follow a proton pump inhibitor (PPI) medication regimen to manage GERD symptoms.
1 procedure visit for ARMV group; ongoing medication use with monitoring for PPI group
Follow-up
Duration - Up to 36 months
Participants are followed for up to 36 months to monitor symptoms, medication use, and any adverse events.
Visits at 3, 6, 12, 24, and 36 months for symptom and safety assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Retrospective Analysis of Chinese Adults With Gastroesophageal Reflux Disease Using a National Clinical Database Characterizing Patient Profiles, Treatments, and Long-Term Outcomes
Comparing Anti-reflux Mucosal Valvuloplasty to Proton Pump Inhibitors for Treating Gastroesophageal Reflux Disease in Adults Aged 18 to 60
Comparing Tegoprazan and Pantoprazole for Treating Gastroesophageal Reflux Disease in Adults
Study of Dietary and Behavioral Management Strategies for Gastroesophageal Reflux Disease to Improve Symptoms and Quality of Life
Study Comparing Modified and Conventional Vertical Sleeve Gastrectomy to Reduce Acid Reflux After Surgery and Improve Quality of Life
Evaluating an Online Mindfulness Program for Emotional Distress and Symptoms in Adults with Gastroesophageal Reflux Disease in a Randomized Controlled Trial
Predicting Symptom Improvement After Laparoscopic Fundoplication for Gastroesophageal Reflux Disease A Prospective Observational Study
Study to Understand Factors Causing and Progressing Gastroesophageal Reflux Disease and Barretts Esophagus with Creation of a Patient Registry
Comparing Two Surgical Methods for Gastric Cancer Anterior Anastomosis with Pyloroplasty vs. Esophagogastric Anastomosis after Proximal Gastrectomy
Study on How Long-Term Diet and Behavior Affect Gastroesophageal Reflux Disease Symptoms and Outcomes
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Antireflux mucosal valvuloplasty versus proton pump inhibitors for the treatment of patients with gastro-oesophageal reflux disease in a tertiary healthcare centre in China: study protocol for a randomised controlled trial.